Furthermore, genetically predicted estrogen receptor-negative breast cancer (ER-BC) is associated with an elevated risk of IBD overall (OR = 1.153; 95% CI: 1.008-1.319; p = 0.037) (Figure 4). Here, ESR1 is linked to inflammatory bowel disease.